ChromoCure Finalizes Merger & Acquisition With GRG Valued at $29,000,000 - New Entity to Lead Cancer Detection, Therapy and Cure
2010年5月7日 - 2:41AM
Marketwired
ChromoCure, Inc. (PINKSHEETS: KKUR) and Genome Research Group
announce today completing their previously announced Merger and
Acquisition Agreement. The Companies combine to create a new era in
cancer research.
The Agreement has a final valuation of $29,000,000 representing
the valuation of the GRG operations and assets, including GRG's
proprietary advanced therapeutic modeling protocols and algorithms
utilizing hypothermic modulation and resonance. Included also is
GRG's therapeutic results and findings, methodologies and
proprietary knowledge in the non-toxic and non-invasive treatment
of cancer.
The updated financials reflecting the $29 million asset
acquisition, merger and resultant share restructuring, together
with updates on name change, new website and other operational
updates will be released as part of the Company's ongoing OTC
disclosure practices.
The amalgamate company, under new GRG management, will integrate
both Companies' operations and Intellectual Property (IP) assets,
be renamed Genome Research Group and move its main operations to
GRG's base in London, UK. The Company will continue its
collaboration and research initiatives in the United States as well
as expanding these efforts throughout Europe.
The combined entity will possess complementary detection and
therapeutic technology and protocols, comprised of ChromoCure's
advanced detection system and GRG's full line of therapeutic
protocols and technology; allowing for the first time real-time
progression monitoring and remission detection -- providing the
world's first cure research fully integrated system for the precise
measurement of treatment and results.
Management believes the transaction to be of significant
long-term shareholder value and furthers the Company's transition
to research, technology development, and licensing as a source of
significant long-term and recurring revenues and equity
appreciation.
The Company believes its technologies provide the foundation for
significant advances in diagnosis, therapy and cure. The Company
recently announced its Therapy and Cure initiatives with Project
Boveri: Find the Cure. Shareholders can expect further updates on
research collaborations, laboratory partnerships, and research
initiatives.
In line with the Company's goal is to establish a worldwide
network of diagnostic and research collaborations with continuous
collection of cancer specimen and test result data, the Company
recently announced the Euro Zone launch of its Pathologist
Collaborative Research (PCR) Program in support of the
groundbreaking Project Boveri: Find the Cure Initiative; as the
companies leverage their combined technologies, research knowledge
and industry relationships.
About Genome Research Group, Inc. The
Company develops and provides proprietary cancer detection systems
and related therapeutic technologies. The Company's proprietary
cancer detection system locates and measures unique genomic
characteristic found in 100% of all cancers and never found in
normal cells. The Company's detection technology has a proven and
effective accuracy of 100% for all cancers at all stages. The
Company's proprietary Therapeutic Modeling Protocols provide
statistical modeling and prediction tools for the measurement and
monitoring of cancer progression and remission. The Company also
applies its technology and knowledge to cancer cure and
therapeutics research. The Company owns proprietary cancer
detection systems and related therapeutic technologies and
proprietary techniques for non-toxic and non-invasive cancer
therapy utilizing hypothermic modulation and resonance. The
Company's proprietary CS200 Chromosomal Scanner has been proven
accurate and efficient in the measurement of the unique genomic
characteristic found in 100% of all cancers and never found in
normal cells. The Company's detection technology has an effective
accuracy of 100% for all cancers at all stages. GRG's advanced
Therapeutic Modeling and Treatment Protocols combined with its
industry and medical research collaborations validate its
leadership role in Cancer Detection, Therapy and Cure.
The Company believes its technology will become the worldwide
gold standard for cancer detection, progression measurement, and
research for both therapy and cure. The Company also applies its
technology and knowledge to cancer cure and therapeutics
research.
Safe-Harbor Statement This release
contains statements or projections regarding future performance
that is forward-looking statements as defined in the Private
Securities Litigation Reform Act of 1995. Actual results may differ
materially from those projected as a result of certain risks and
uncertainties. The company's filings contain various RISK FACTORS
(and are incorporated herein by reference) and should be read
before any investment decision.
ChromoCure, Inc. (to be renamed Genome Research Group,
Inc.) www.ChromoCure.com www.GenomeResearchGroup.com
info@genomeresearchgroup.com Tel: +011 (44) 20 7101 9475
Chromocure (CE) (USOTC:KKUR)
過去 株価チャート
から 5 2024 まで 6 2024
Chromocure (CE) (USOTC:KKUR)
過去 株価チャート
から 6 2023 まで 6 2024